Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts - Iwata, H; Tamura, K; Doi, T (J Clin Oncol, 2018)
et al.